Skip to content

Study · Animal study (in vivo) · mouse · 2021

8 results

Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better.

Sanada J, Obata A, Obata Y, Fushimi Y, Shimoda M, Kohara K, Nakanishi S, Mune T, Kaku K, Kaneto H

Scientific reports14 Jan 2021Cited by 36 (Europe PMC)

PMID33446799 (opens in a new tab)PMCIDPMC7809053 (opens in a new tab)DOI10.1038/s41598-020-80894-x (opens in a new tab)PepBankPUB-33446799
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

There has been no report about the mechanism for anti-atherosclerotic effects of dulaglutide (Dula) and/or about the difference of its effectiveness between in an early and a late phase of diabetes. To address such questions, streptozotocin (STZ) was intraperitoneally injected to ApoE knockout mice at 8 weeks of age. Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group. Next, non-diabetic ApoE knockout mice without STZ injection were subcutaneously injected with either Dula or vehicle. In an early intervention group, atherosclerotic lesion in aortic arch and Mac-2 and CD68-positive areas in aortic root were significantly smaller in Dula group. In abdominal aorta, expression levels of some villain factors were lower in Dula group. In a late intervention group, there were no immunohistological differences in aortic root and expression levels of various factors between two groups. Furthermore, even in non-diabetic ApoE knockout mice, expression levels of inflammatory and macrophage markers were reduced by treatment with Dula. Taken together, Dula exerts more beneficial anti-atherosclerotic effects in an early phase of diabetes rather than in a late phase.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ApoE knockout mice, early dulaglutide reduced aortic arch lesions versus vehicle.

    In plain wordsIn mice with diabetes, early dulaglutide reduced artery lesions compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAortic arch atherosclerotic lesion
    Study

    mousen: not reported in source

    STZ-induced diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 10 to 18 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    In an early intervention group, atherosclerotic lesion in aortic arch and Mac-2 and CD68-positive areas in aortic root were significantly smaller in Dula group.
    1 context sentence
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ApoE knockout mice, early dulaglutide reduced aortic root Mac-2-positive areas versus vehicle.

    In plain wordsIn mice with diabetes, early dulaglutide reduced a macrophage marker area compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMac-2-positive area
    Study

    mousen: not reported in source

    STZ-induced diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 10 to 18 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    In an early intervention group, atherosclerotic lesion in aortic arch and Mac-2 and CD68-positive areas in aortic root were significantly smaller in Dula group.
    1 context sentence
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ApoE knockout mice, early dulaglutide reduced aortic root CD68-positive areas versus vehicle.

    In plain wordsIn mice with diabetes, early dulaglutide reduced a macrophage marker area compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseCD68-positive area
    Study

    mousen: not reported in source

    STZ-induced diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 10 to 18 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    In an early intervention group, atherosclerotic lesion in aortic arch and Mac-2 and CD68-positive areas in aortic root were significantly smaller in Dula group.
    1 context sentence
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ApoE knockout mice, early dulaglutide lowered expression of unspecified adverse factors in abdominal aorta versus vehicle.

    In plain wordsIn mice with diabetes, early dulaglutide lowered unspecified harmful factor expression in arteries compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseAbdominal aortic factor expression
    Study

    mousen: not reported in source

    STZ-induced diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 10 to 18 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    In abdominal aorta, expression levels of some villain factors were lower in Dula group.
    1 context sentence
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ApoE knockout mice, late dulaglutide did not change aortic root immunohistology versus vehicle.

    In plain wordsIn mice with diabetes, late dulaglutide did not change artery tissue staining compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeLate aortic root immunohistology
    Study

    mousen: not reported in source

    STZ-induced diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 18 to 26 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    In a late intervention group, there were no immunohistological differences in aortic root and expression levels of various factors between two groups.
    1 context sentence
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic ApoE knockout mice, late dulaglutide did not change factor expression versus vehicle.

    In plain wordsIn mice with diabetes, late dulaglutide did not change measured factor expression compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeLate factor expression
    Study

    mousen: not reported in source

    STZ-induced diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · 18 to 26 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    In a late intervention group, there were no immunohistological differences in aortic root and expression levels of various factors between two groups.
    1 context sentence
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic ApoE knockout mice, dulaglutide reduced inflammatory marker expression versus vehicle.

    In plain wordsIn mice without diabetes, dulaglutide reduced inflammation marker expression compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseInflammatory markers
    Study

    mousen: not reported in source

    Non-diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, even in non-diabetic ApoE knockout mice, expression levels of inflammatory and macrophage markers were reduced by treatment with Dula.
    2 context sentences
    Summary · context
    Next, non-diabetic ApoE knockout mice without STZ injection were subcutaneously injected with either Dula or vehicle.
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In non-diabetic ApoE knockout mice, dulaglutide reduced macrophage marker expression versus vehicle.

    In plain wordsIn mice without diabetes, dulaglutide reduced macrophage marker expression compared with vehicle.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMacrophage markers
    Study

    mousen: not reported in source

    Non-diabetic ApoE knockout mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · subcutaneousAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, even in non-diabetic ApoE knockout mice, expression levels of inflammatory and macrophage markers were reduced by treatment with Dula.
    2 context sentences
    Summary · context
    Next, non-diabetic ApoE knockout mice without STZ injection were subcutaneously injected with either Dula or vehicle.
    Summary · context
    Either Dula or vehicle was administered to STZ-induced diabetic ApoE knockout mice from 10 to 18 weeks of age as an early intervention group and from 18 to 26 weeks as a late intervention group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.